{
    "nct_id": "NCT06055894",
    "official_title": "Microbial Changes in Response to a Plant Based Diet and/or Supplements in SMM/MGUS Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via HealthTree",
    "inclusion_criteria": "* Confirmed prior diagnosis MGUS or of smoldering myeloma (anytime prior). However, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment.\n* Age ≥18 years\n* Willingness to comply with all study-related procedures\n* Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion)\n* Interested in learning to cook plant based recipes\n* Access to smart mobile phone or device with camera and ability to download Keenoa app\n* Be residing within the United States for the study duration.\n* English speaking or a family member or caregiver who speaks English and is able to assist with the surveys and phone based Keenoa app.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Taking any supplements other than vitamin D, iron, vitamin B12, potassium, magnesium, calcium or those needed for a medical indication must be reviewed by PI. If patient is on a supplement (including curcumin, probiotic, omega3) they must stop these for 2 weeks prior to enrollment on study.\n* Patients that already follow a whole foods plant based diet (ovo-lactovegetarian or processed junk food vegan diets are not excluded). This will be per research dietitian evaluation and discretion after nutrition screening.\n* Legume allergy\n* Severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews\n* Concurrent participation in weight loss/dietary trials or defined programs (that require specified diets/supplements on the program)\n* Concurrent use of prescription weight loss (such as semaglutides and tirzepatides) and/or therapeutic myeloma drugs such as daratumumab, lenalidomide, etc.) within 12 weeks of consent\n* Mental impairment leading to inability to cooperate\n* Enrollment onto any other therapeutic investigational study\n* Concurrent pregnancy\n* Patients on full dose anticoagulation\n* ≥ Grade 2 electrolyte (sodium and potassium) abnormalities as defined by CTCAEv5.0 (need to be resolved before enrolling on study)\n* If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely\n* Current self reported heavy alcohol use (defined as >2 drinks per day or >14 drinks per week)\n* Current self-reported illicit drug use (except inhaled marijuana, vaping or cigarette smoking. Oral marijuana/THC excluded or must stop >2 weeks prior.)\n* Has a condition requiring antibiotics within 14 days of study intervention administration.\n* Plan for travel during the study that would preclude adherence to prescribed diets\n* History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted)",
    "miscellaneous_criteria": ""
}